SALOFALK 1.5 g PROLONGED-RELEASE GRANULES
How to use SALOFALK 1.5 g PROLONGED-RELEASE GRANULES
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Salofalk 1.5 g Prolonged-Release Granules
Mesalazine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack and other information
- What Salofalk 1.5 g granules are and what they are used for
- What you need to know before you take Salofalk 1.5 g granules
- How to take Salofalk 1.5 g granules
- Possible side effects
- Storing Salofalk 1.5 g granules
Contents of the pack and further information
1. What Salofalk 1.5 g granules are and what they are used for
Salofalk granules contain the active substance mesalazine, an anti-inflammatory that is used to treat inflammatory bowel diseases.
Salofalk 1.5 g granules are used for:
Treatment of acute episodes and prevention of new episodes (relapses) of mild to moderate ulcerative colitis, a chronic inflammatory disease of the large intestine (colon).
2. What you need to know before you take Salofalk 1.5 g granules
Do not take Salofalk granules:
- If you are allergic to mesalazine, salicylic acid, salicylates such as acetylsalicylic acid (e.g. Aspirin) or any of the other ingredients of this medicine (listed in section 6).
- If you have severe liver or kidney disorders.
Warnings and precautions
Consult your doctor before starting to take Salofalk 1.5 g granules:
- if you have a history of lung disease, particularly if you suffer from bronchial asthma
- if you have a history of allergy to sulfasalazine, a substance related to mesalazine
- if you have liver problems
- if you have kidney problems
- If you have ever suffered from a severe skin rash, skin peeling, blisters, or ulcers in the mouth after using mesalazine
- Mesalazine may cause a discoloration of the urine to a reddish-brown color after contact with sodium hypochlorite bleach in the toilet water. This is a chemical reaction between mesalazine and the bleach and is harmless.
Additional precautions
During treatment, your doctor may want to keep you under medical supervision, and you may need to have regular blood and urine tests.
Kidney stones may occur with the use of mesalazine. The symptoms include pain in the sides of the abdomen and blood in the urine. Make sure to drink a sufficient amount of liquid during treatment with mesalazine
Severe skin reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SSJ), and toxic epidermal necrolysis (TEN), have been observed with mesalazine treatment. Stop taking mesalazine and seek medical attention immediately if you observe any of the symptoms related to these severe skin reactions described in section 4.
Using Salofalk 1.5 g granules with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, in particular:
- Azathioprine, 6-mercaptopurine, or thioguanine(medicines for treating immune system disorders)
- Certain agents that inhibit blood coagulation(medicines for thrombosis or to thin the blood, such as warfarin)
- Lactulose(a medicine used for constipation) or other preparations that may change the acidity of your stools
Tell your doctor or pharmacist if you are using or have recently used other medicines, even those bought without a prescription. It may still be all right for you to use Salofalk granules, and your doctor will be able to decide what is best for you.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
You should use Salofalk granules during pregnancy only if your doctor has told you to.
Also, you should only use Salofalk granules during breastfeeding if your doctor has told you to, as this medicine may pass into breast milk.
Driving and using machines
Salofalk granules have no or negligible influence on the ability to drive and use machines.
Salofalk 1.5 g granules contain aspartame, sucrose, and sodium
This medicine contains 3 mg of aspartame in each sachet of Salofalk 1.5 g granules. Aspartame is a source of phenylalanine that may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body cannot eliminate it properly.
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per sachet; this is essentially “sodium-free”.
3. How to take Salofalk 1.5 g granules
Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, consult your doctor or pharmacist again.
Method of administration
Salofalk granules are for oral use only.
Salofalk granules must not be chewed. The granules should be taken by placing them directly on the tongue and then swallowing them with plenty of liquid, without chewing.
Posology
Age and body weight | Single dose | Total daily dose |
Adults, elderly, and children over 40 kg body weight | ||
Treatment of acute episodes | Up to 2 sachets of Salofalk 1.5 g granules | 1 x 1-2 sachets |
Prevention of new episodes (for patients with higher risk of relapse) | 2 sachets of Salofalk 1.5 g granules | 1 x 2 sachets |
Adults and elderly
Unless your doctor has prescribed otherwise, the usual dosage for the treatment of acute episodes of ulcerative colitis is 1-2 sachets of Salofalk 1.5 g granules once daily, preferably in the morning (equivalent to 1.5 to 3 g of mesalazine per day), depending on the individual clinical requirements.
For the prevention of relapses of ulcerative colitis
The usual dosage for preventing new episodes of ulcerative colitis is:
1 sachet of Salofalk 500 mg granules three times a day (equivalent to 1.5 g of mesalazine per day)
If your doctor considers that you have a higher risk of relapse, the dosage for preventing new episodes of ulcerative colitis is:
2 sachets of Salofalk 1.5 g granules once daily, preferably in the morning (equivalent to 3 g of mesalazine per day).
Use in children
There is only limited documentation on the effect in children (from 6 to 18 years).
Children from 6 years and older
Please ask your doctor about the correct dosage of Salofalk granules for your child.
In acute episodes
The dose should be determined individually, starting with 30-50 mg of mesalazine per kg body weight and per day, which should be administered once daily, preferably in the morning, or divided into several doses. The maximum dose is 75 mg of mesalazine per kg body weight per day. The total dose should not exceed the maximum dose in adults.
It is generally recommended to use half the adult dose for children up to 40 kg and the normal adult dose for children over 40 kg body weight.
Due to its high active substance content, Salofalk 1.5 g granules are not suitable for children weighing less than 40 kg. Instead, use Salofalk 500 mg or 1000 mg granules.
Duration of treatment
Treatment of acute episodes of ulcerative colitis usually lasts 8 weeks. Your doctor will decide how long you need to continue treatment with this medicine, depending on the course of your disease.
In order to achieve the maximum therapeutic effects of this medicine, you should take Salofalk granules regularly and systematically, both during the acute episode of inflammation and during long-term treatment as prescribed.
If you think that Salofalk granules are too strong or too weak, consult your doctor.
If you take more Salofalk granules than you should
Contact your doctor if you are unsure what to do. If you have taken too much Salofalk granules in one go, just take the next dose as prescribed. Do not take a smaller dose.
If you forget to take Salofalk granules
Do not take a double dose to make up for forgotten doses.
If you stop taking Salofalk granules
Do not stop taking this medicine without talking to your doctor first.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, Salofalk granules can cause side effects, although not everybody gets them.
If you experience any of the following symptoms after taking this medicine, you should contact your doctor and stop taking Salofalk granules immediately:
- General allergic reactions such as skin rash, fever, joint pain, and/or difficulty breathing or a general inflammation of the large intestine (causing severe diarrhea and abdominal pain). These reactions are very rare.
- A significant worsening of your general health, especially if accompanied by fever and/or sore throat and mouth. These symptoms, very rarely, can be caused by a decrease in the number of white blood cells in the blood (agranulocytosis), which can increase your propensity to contract a serious infection. Other blood cells (such as platelets and red blood cells) may also be affected, causing symptoms such as unexplained bleeding, small purple spots on the skin, and anemia (feeling tired and weak and pale, especially in the lips and nails). A blood test can confirm whether the symptoms are due to an effect of this medicine on the blood. These reactions are very rare.
- Severe skin reactions with reddish, circular, or target-shaped patches on the trunk, often with central blisters, skin peeling, ulcers in the mouth, throat, nose, genitals, and eyes, generalized rash, fever, and enlargement of the lymph nodes. They can be preceded by fever and flu-like symptoms. These reactions occur in an unknown number of people (frequency not known).
- Difficulty breathing, chest pain, or irregular heartbeat, or swelling of the limbs, which may indicate cardiac hypersensitivity reactions. These reactions are rare.
- Kidney problems (which can occur very rarely), such as a change in the color or amount of urine produced and swelling of the limbs or sudden pain in the side (caused by a kidney stone) (occurs in an unknown number of people (frequency not known).
The following side effects have also been reported by patients using mesalazine:
Common side effects (may affect up to 1 in 10 people)
Headache
Skin rash, itching
Uncommon side effects (may affect up to 1 in 100 people)
Abdominal pain, diarrhea, dyspepsia, gas (flatulence), nausea, and vomiting
Severe abdominal pain due to acute pancreatitis
Changes in liver function parameters, changes in pancreatic enzymes
Rare side effects (may affect up to 1 in 1,000 people)
Dizziness
Jaundice or abdominal pain due to liver or bile duct disorders
Increased sensitivity of the skin to sunlight and ultraviolet light (photosensitivity).
Joint pain
Feeling weak or tired
Very rare side effects (may affect up to 1 in 10,000 people)
Numbness and tingling in hands and feet (peripheral neuropathy)
Shortness of breath, cough, wheezing, lung shadow on X-rays due to allergic and/or inflammatory lung conditions
Hair loss and development of baldness
Muscle pain
Reversible decrease in sperm production
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Surveillance System for Human Use: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storing Salofalk 1.5 g granules
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and sachets after EXP. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
6. Contents of the pack and further information
Composition of Salofalk 1.5 g granules
The active substance of Salofalk 1.5 g granules is mesalazine, and one sachet of Salofalk 1.5 g granules contains 1.5 g of mesalazine.
The other ingredients are: aspartame (E 951); carmellose sodium; microcrystalline cellulose; citric acid; colloidal anhydrous silica; hypromellose; magnesium stearate; methacrylic acid - methyl methacrylate copolymer (1:1) (Eudragit L 100); methylcellulose; polyacrylate dispersion 40% (Eudragit NE 40 D containing 2% nonoxinol 100); povidone K 25; simethicone; sorbic acid; talc; triethyl citrate; vanilla cream flavor (containing sucrose).
Appearance of the product and pack contents
The granules of Salofalk 1.5 g prolonged-release granules are rounded or elongated, beige or brown in color, with or without yellowish surface parts.
Each sachet contains 2.74 g of granules.
Salofalk 1.5 g granules are available in packs of 20, 30, 35, 45, 50, 60, 70, 90, 100, and 150 sachets.
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Dr. Falk Pharma GmbH
Leinenweberstr. 5
79108 Freiburg
Germany
Tel +49 (0) 761 / 1514-0
Fax +49(0) 761 / 1514-321
E-mail: [email protected]
You can obtain further information on this medicine from the representative of the marketing authorisation holder:
Spain
Dr. Falk Pharma España
Camino de la Zarzuela, 19-1º D28023 Madrid
Tel +34 913 729 508
Fax +34 913 729 437
E-mail: [email protected]
This medicine is authorised in the Member States of the European Economic Area under the following names:
Germany, Bulgaria, Denmark, Slovakia, Slovenia, Spain, Finland, Greece, Hungary, Ireland, Italy, Latvia, Norway, Netherlands, Poland, Portugal, United Kingdom, Czech Republic, and Sweden: Salofalk.
Belgium, Luxembourg: Colitofalk.
Austria: Mesagran.
France: Osperzo.
Date of last revision of this leaflet: May 2025
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.es/
- Country of registration
- Dosage formMODIFIED-RELEASE POWDER/GRANULATE, 1500 mg
- ATC codeA07EC02
- Average pharmacy price119.77 EUR
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to SALOFALK 1.5 g PROLONGED-RELEASE GRANULESDosage form: SUPPOSITORY, 1 gActive substance: mesalazineManufacturer: Tillotts Pharma Spain S.L.U.Prescription requiredDosage form: TABLET, 1600 mgActive substance: mesalazineManufacturer: Tillotts Pharma Spain S.L.U.Prescription requiredDosage form: TABLET, 400 mgActive substance: mesalazineManufacturer: Tillotts Pharma Spain S.L.U.Prescription required
Online doctors for SALOFALK 1.5 g PROLONGED-RELEASE GRANULES
Discuss questions about SALOFALK 1.5 g PROLONGED-RELEASE GRANULES, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
